Dupixent

First-line systemic therapy for the long-term treatment of atopic dermatitis - see dupilumab.

Approved for children with severe atopic dermatitis 6-11 years of age, approval on 11/25/2020.

For adolescents 12 years and older, approval since August 2019.

for adults since September 2017.

Adults: 600 mg initially and 300 mg every 2 weeks

Adolescents (12-17 years) under 60 kg: 400 mg initially and 200 mg every 2 weeks

over 60 kg 600 mg initially and 300 mg every 2 weeks

Children 6-11 years 15-60 kg: 300 mg on day 1 and day 15 - thereafter (4 weeks after 2nd dose) every 4 weeks 300 mg

>> 60 kg: 600 mg initially and 300 mg every 2 weeks

Most UAW`s were passager mild to moderate. With dupilumab, naso-laryngo-pharyngitis, conjunctivitis (28% of pat Aszodi N et al 2019), headache, herpes simplex infections, and injection site inflammatory reactions were more common.

Associated ocular diseases: blepharitis, lid margin inflammation.

Recommended therapy: eyelid rim care with heat packs (45°C)

Eyelid massage (stroking out the meibomian glands with closed eyelids), eyelid cleansing with cotton pad,

Tear substitute - in case of no improvement ophthalmologist - if necessary therapy with local steroids or eye drops containing cildosporin (Ikervis®AT)

1. Wohlrab J et al (2019) Interdisciplinary recommendations for action in dupilumab-associated inflammatory eye diseases [Interdisciplinary recommendations for action in dupilumab-related inflammatory eye diseases]. Dermatologist. 70:64-67
2. Aszodi N et al. (2019) Management of dupilumab-associated conjunctivitis in atopic dermatitis. J Dtsch Dermatol Ges 17:488-491.